{"id":"iobenguane-i-123-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"},{"rate":null,"effect":"Allergic reaction to iodine"},{"rate":null,"effect":"Hypertensive crisis (in pheochromocytoma patients)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iobenguane I-123 mimics norepinephrine and is taken up by the norepinephrine transporter (NET) on neuroendocrine cells, concentrating in tumors with high sympathetic innervation or neuroendocrine differentiation. The iodine-123 radioisotope emits gamma radiation that is detected by SPECT cameras, enabling visualization and localization of neuroendocrine tumors. This mechanism makes it useful for both diagnostic imaging and risk stratification in neuroendocrine malignancies.","oneSentence":"Iobenguane I-123 is a radiolabeled norepinephrine analog that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing for diagnostic imaging via single-photon emission computed tomography (SPECT).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:00.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diagnostic imaging of neuroendocrine tumors, including pheochromocytoma and paraganglioma"},{"name":"Imaging of neuroblastoma in pediatric patients"}]},"trialDetails":[{"nctId":"NCT07064746","phase":"","title":"Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-07-10","conditions":"Neuroblastoma (NB)","enrollment":150},{"nctId":"NCT04510311","phase":"EARLY_PHASE1","title":"Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-10-19","conditions":"Neuroendocrine Tumors","enrollment":32},{"nctId":"NCT01250912","phase":"NA","title":"Imaging With a Radio Tracer to Guide VT Ablations","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-03","conditions":"Ventricular Tachycardia, Arrhythmia","enrollment":20},{"nctId":"NCT02043899","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma","status":"COMPLETED","sponsor":"Cancer Research UK","startDate":"2014-02","conditions":"Metastatic Neuroblastoma","enrollment":36},{"nctId":"NCT00126412","phase":"PHASE3","title":"Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2005-08-02","conditions":"Pheochromocytoma, Neuroblastoma","enrollment":251},{"nctId":"NCT02656329","phase":"PHASE3","title":"International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device","status":"TERMINATED","sponsor":"GE Healthcare","startDate":"2015-12-30","conditions":"Heart Failure","enrollment":395},{"nctId":"NCT02043522","phase":"PHASE3","title":"123I-mIBG SPECT Imaging","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2013-12","conditions":"Heart Failure, Coronary Artery Disease","enrollment":30},{"nctId":"NCT02071680","phase":"PHASE3","title":"Autonomic Innervation and MIBG Imaging","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2015-03","conditions":"Atrial Fibrillation","enrollment":5},{"nctId":"NCT01936649","phase":"PHASE4","title":"Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.","status":"COMPLETED","sponsor":"GE Healthcare","startDate":"2013-08","conditions":"Heart Failure (HF), Ventricular Dysfunction, Left","enrollment":63},{"nctId":"NCT01432626","phase":"NA","title":"Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2011-09","conditions":"Stress Induced Cardiomyopathy","enrollment":10},{"nctId":"NCT00730444","phase":"","title":"Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma","status":"APPROVED_FOR_MARKETING","sponsor":"GE Healthcare","startDate":"","conditions":"Neuroblastoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AdreView","Iobenguane I-123 Injection"],"phase":"phase_3","status":"active","brandName":"Iobenguane I -123 Injection","genericName":"Iobenguane I -123 Injection","companyName":"GE Healthcare","companyId":"ge-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iobenguane I-123 is a radiolabeled norepinephrine analog that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing for diagnostic imaging via single-photon emission computed tomography (SPECT). Used for Diagnostic imaging of neuroendocrine tumors, including pheochromocytoma and paraganglioma, Imaging of neuroblastoma in pediatric patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}